Daybreak Health vs Moderna
Side-by-side comparison of AI visibility scores, market position, and capabilities
SF YC W20 school-based teletherapy for students with 60+ district partnerships; $25M total ($13M USV/Lux/Lightspeed Series B Aug 2023) competing with Hazel Health and Brightline for school district mental health access.
About
Daybreak Health is a San Francisco-based school-based teletherapy platform — backed by Y Combinator (W20) with $25 million in total funding including a $13 million Series B in August 2023 led by Union Square Ventures with Lux Capital, Lightspeed Venture Partners, Maven Ventures, and Y Combinator, following a $10 million Series A in 2022 and $1.8 million seed in 2021 — providing school districts with high-quality, affordable, and culturally competent virtual mental health therapy for students, partnering with 60+ school districts since 2019 to address the student mental health crisis through personalized counseling delivered by licensed therapists through telehealth. Founded in 2019, Daybreak positions as the leading school-based teletherapy provider focused on making mental health support accessible to all students regardless of socioeconomic status.
mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.
About
Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.